Nuvectis Pharma, Inc.
NVCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875558
No open-market purchases or sales by Nuvectis Pharma, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $189.0M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Nuvectis Pharma, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 62 | 2 | 82 | +22 |
| Shares | 4.49M | 171 | 10.2M | +5.68M (+126.4%) |
| Value | $34.9M | $1.32K | $189.0M | +$154.0M (+440.9%) |
2 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (28)
Institutions that held Nuvectis Pharma, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
Sold out (6)
Institutions that held Nuvectis Pharma, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Marshall Wace, LLP | 29,223 | $225.9K |
| Edmond de Rothschild Holding S.A. | 15,170 | $117.3K |
| Nations Financial Group Inc, | 13,000 | $100.5K |
| XTX Topco Ltd | 10,066 | $77.8K |
| Spire Wealth Management | 300 | $2.32K |
| MAI Capital Management | 9 | $70 |
Not filed for Q2 2026 yet (2)
Institutions that held Nuvectis Pharma, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| CWM, LLC | 170 | $1.31K |
| Sunbelt Securities, Inc. | 1 | $8 |